<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Rheum Dis</journal-id><journal-id journal-id-type="iso-abbrev">Ann. Rheum. Dis</journal-id><journal-id journal-id-type="hwp">annrheumdis</journal-id><journal-id journal-id-type="publisher-id">ard</journal-id><journal-title-group><journal-title>Annals of the Rheumatic Diseases</journal-title></journal-title-group><issn pub-type="ppub">0003-4967</issn><issn pub-type="epub">1468-2060</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name><publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23942869</article-id><article-id pub-id-type="pmc">3888591</article-id><article-id pub-id-type="publisher-id">annrheumdis-2013-203697</article-id><article-id pub-id-type="doi">10.1136/annrheumdis-2013-203697</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject></subj-group><subj-group subj-group-type="heading"><subject>Clinical and Epidemiological Research</subject></subj-group><series-title>Concise report</series-title></article-categories><title-group><article-title>Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>van der Heijde</surname><given-names>D</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fleischmann</surname><given-names>R</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wollenhaupt</surname><given-names>J</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Deodhar</surname><given-names>A</given-names></name><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Kielar</surname><given-names>D</given-names></name><xref ref-type="aff" rid="af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Woltering</surname><given-names>F</given-names></name><xref ref-type="aff" rid="af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Stach</surname><given-names>C</given-names></name><xref ref-type="aff" rid="af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Hoepken</surname><given-names>B</given-names></name><xref ref-type="aff" rid="af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Arledge</surname><given-names>T</given-names></name><xref ref-type="aff" rid="af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Mease</surname><given-names>P J</given-names></name><xref ref-type="aff" rid="af8">8</xref></contrib></contrib-group><aff id="af1"><label>1</label><addr-line>Department of Rheumatology</addr-line>, <institution>Leiden University Medical Centre</institution>, <addr-line>Leiden</addr-line>, <country>The Netherlands</country></aff><aff id="af2"><label>2</label><institution>University of Texas SW Medical Center</institution>, <addr-line>Dallas, Texas</addr-line>, <country>USA</country></aff><aff id="af3"><label>3</label><institution>Schoen Klinik</institution>, <addr-line>Hamburg</addr-line>, <country>Germany</country></aff><aff id="af4"><label>4</label><addr-line>Division of Arthritis/Rheumatic Diseases (OPO9)</addr-line>, <institution>Oregon Health &#x00026; Science University</institution>, <addr-line>Portland, Oregon</addr-line>, <country>USA</country></aff><aff id="af5"><label>5</label><institution>UCB Pharma</institution>, <addr-line>Brussels</addr-line>, <country>Belgium</country></aff><aff id="af6"><label>6</label><institution>UCB Pharma</institution>, <addr-line>Monheim am Rhein</addr-line>, <country>Germany</country></aff><aff id="af7"><label>7</label><institution>UCB Pharma</institution>, <addr-line>Raleigh, North Carolina</addr-line>, <country>USA</country></aff><aff id="af8"><label>8</label><institution>Swedish Medical Center and University of Washington</institution>, <addr-line>Seattle, Washington</addr-line>, <country>USA</country></aff><author-notes><fn><p><bold>Handling editor</bold> Tore K Kvien</p></fn><corresp><label>Correspondence to</label> Professor D&#x000e9;sir&#x000e9;e van der Heijde, Department of Rheumatology, Leiden University Medical Center, PO Box 9600, Leiden 2300 RC, The Netherlands; Email: <email>mail@dvanderheijde.nl</email></corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>13</day><month>8</month><year>2013</year></pub-date><volume>73</volume><issue>1</issue><fpage>233</fpage><lpage>237</lpage><history><date date-type="received"><day>27</day><month>3</month><year>2013</year></date><date date-type="rev-recd"><day>12</day><month>6</month><year>2013</year></date><date date-type="accepted"><day>26</day><month>6</month><year>2013</year></date></history><permissions><copyright-statement>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access"><license-p>This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link></license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="annrheumdis-2013-203697.pdf"/><related-article id="d35e282" related-article-type="companion" ext-link-type="doi" xlink:href="10.1136/annrheumdis-2013-203696"/><related-article id="d35e283" related-article-type="companion" ext-link-type="doi" xlink:href="10.1136/annrheumdis-2013-204231"/><abstract><sec><title>Objectives</title><p>To report the effect of different imputation methodologies on the assessment of radiographic progression in clinical trials.</p></sec><sec><title>Methods</title><p>The 216-week RAPID-psoriatic arthritis (PsA) (NCT01087788) trial of certolizumab pegol (CZP) in patients with active PsA was double-blind and placebo-controlled until week 24. A primary end point was change from baseline in modified Total Sharp Score(s) (mTSS). Prespecified imputation methodology in patients with fewer than two analysable mTSS used minimum observed baseline score for missing baseline values and maximum observed week 24 score for missing week 24 values. Post hoc analyses used alternative methods of imputation in patients with fewer than two analysable mTSS. mTSS non-progressors were defined as patients with &#x02264;0 (predefined) or &#x02264;0.5 (post hoc) change in mTSS from baseline to week 24. Baseline mTSS and C-reactive protein levels as predictors of radiographic progression were investigated.</p></sec><sec><title>Results</title><p>409 patients were randomised. Baseline demographics were similar between groups. Prespecified imputation analysis inappropriately overestimated radiographic progression (least squares mean placebo, 28.9; CZP, 18.3; p&#x02265;0.05). Multiple post hoc analyses demonstrated that CZP inhibited radiographic progression compared with placebo, particularly in patients with high baseline mTSS and C-reactive protein levels. mTSS non-progression rate was higher in CZP than placebo groups in all analyses.</p></sec><sec><title>Conclusions</title><p>Inappropriate prespecified imputation methodology resulted in an unrealistic assessment of progression in all arms. Methodologies for imputing missing radiographic data can greatly affect assessment and reporting of mTSS progression.</p></sec></abstract><kwd-group><kwd>Anti-TNF</kwd><kwd>Psoriatic Arthritis</kwd><kwd>Outcomes research</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>special-feature</meta-name><meta-value>unlocked</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>In clinical practice and clinical trials, structural damage caused by rheumatic diseases, including psoriatic arthritis (PsA), is commonly assessed by radiography.<xref ref-type="bibr" rid="R1 R2 R3 R4">1&#x02013;4</xref> However, progression of structural damage can be difficult to assess accurately in clinical trials.<xref ref-type="bibr" rid="R1">1</xref> Moreover, compared with historic PsA trials, placebo patients in recent trials have very low rates of progression over the double-blind period, with the majority of these patients considered non-progressors.<xref ref-type="bibr" rid="R5">5</xref>
<xref ref-type="bibr" rid="R6">6</xref></p><p>In most placebo-controlled trials, control arm patients are more likely to discontinue therapy because of lack of efficacy compared with those on active treatment. The use of early-escape trial designs, where non-responsive or minimally responsive placebo patients switch to active treatment as early as week 12, creates further imbalance.<xref ref-type="bibr" rid="R1">1</xref>
<xref ref-type="bibr" rid="R7">7</xref> This follow-up period imbalance necessitates the imputation of missing data, particularly radiographic end points, which are typically measured after mandatory withdrawal and escape to active therapy.<xref ref-type="bibr" rid="R1">1</xref></p><p>Linear extrapolation and interpolation, requiring radiographic data from two or more time points, is the most widely used approach to imputing missing radiographic data. Patients with fewer than two data points have historically been excluded from radiographic analyses.<xref ref-type="bibr" rid="R1">1</xref>
<xref ref-type="bibr" rid="R3">3</xref>
<xref ref-type="bibr" rid="R4">4</xref> However, in order to avoid reporting bias, techniques for including patients regardless of data availability are also used in clinical trials.<xref ref-type="bibr" rid="R5">5</xref></p><p>To include data from all patients, a prespecified methodology to impute missing values from patients with fewer than two radiographic time points is necessary.<xref ref-type="bibr" rid="R2">2</xref>
<xref ref-type="bibr" rid="R3">3</xref> Imputation rules, such as using a value from the observed population (mean, median, maximum scores of changes from baseline), can be used to estimate progression in patients with missing radiographic data; however, the impact of these different assumptions on population outcomes has not been published.</p><p>In this article, results from the multinational phase III RAPID-PsA study of certolizumab pegol (CZP) treatment in patients with PsA are presented in order to discuss the effect of different imputation methodologies on the evaluation of radiographic progression.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Patients</title><p>Full details of the ongoing 216-week RAPID-PsA study design (NCT01087788), including the patient population, are reported elsewhere.<xref ref-type="bibr" rid="R8">8</xref> Briefly, 409 adult patients with PsA according to CASPAR criteria<xref ref-type="bibr" rid="R9">9</xref> were recruited. Patients were required to have active musculoskeletal disease, an inadequate response to one or more disease-modifying antirheumatic drug, and active psoriatic skin lesions or a documented history of psoriasis.</p></sec><sec id="s2b"><title>Study design</title><p>RAPID-PsA was double-blind, placebo-controlled to week 24. Patients were randomised 1:1:1 to placebo or 400&#x02005;mg CZP at week 0, 2 and 4 followed by 200&#x02005;mg CZP every 2&#x02005;weeks (Q2W) or 400&#x02005;mg CZP every 4&#x02005;weeks (Q4W). Placebo patients who did not achieve a predefined minimal response at week 14 and week 16 escaped to active treatment at week 16.</p></sec><sec id="s2c"><title>Study procedures and evaluations</title><p>One of the two primary end points was change from baseline to week 24 in the van der Heijde modified Total Sharp Score (mTSS), adapted for PsA.<xref ref-type="bibr" rid="R10">10</xref>&#x000a0;This methodology quantifies the extent of bone erosions and joint space narrowing in distal interphalangeal, proximal interphalangeal, metacarpophalangeal, metatarsophalangeal and wrist joints. Radiographs of both hands and feet were taken at baseline, then at week 12 and week 24 or an early withdrawal visit, using standardised imaging methodology. Radiographs were read centrally and independently by two experienced readers (blinded to treatment assignment and image time course). Discrepancies between readers of &#x02265;10 mTSS points were adjudicated by a third blinded reviewer. The mean of the two independent reviews, or the mean of the adjudicated score and the closest result, was used.</p><p>The proportion of mTSS non-progessors (predefined as &#x02264;0 mTSS change from baseline) was assessed. Post hoc non-progressor analyses used a &#x02264;0.5 mTSS change from baseline definition, based on published guidelines relating to the use of multiple readers.<xref ref-type="bibr" rid="R11">11</xref></p><p>Post hoc subgroup analyses of mTSS change from baseline and mTSS non-progressor rates were also evaluated in patients with a high risk of progression, defined as baseline C-reactive protein (CRP) levels &#x0003e;15&#x02005;mg/L or mTSS higher than the population median.</p></sec><sec id="s2d"><title>Statistical analysis</title><p>The sample size of 130 for each treatment group was sufficient to detect statistically significant differences in the mean change from baseline in the mTSS between the combined active and placebo groups with at least 95% power, assuming a difference of &#x02265;1.0 and a standard deviation (SD) of 2.4 points.</p><p>Treatment comparisons for the combined CZP dose groups versus placebo for change from baseline in mTSS were evaluated using an analysis of covariance model, with treatment, region and prior tumour necrosis factor inhibitor exposure as factors, baseline mTSS as covariate, and mTSS change from baseline as the dependent variable. Linear interpolation and extrapolation of missing data points was used in patients with two or more analysable mTSS, irrespective of time interval between the two scores. Prespecified non-progressor analysis used non-responder imputation (NRI), where placebo patients escaping to CZP and patients withdrawing early from the study were considered mTSS progressors. Post hoc non-progressor analysis used linear interpolation and extrapolation of missing data points for patients with two or more analysable mTSS.</p><p>Prespecified methodology for patients with fewer than two analysable mTSS used the minimum observed baseline mTSS for missing baseline values and the maximum observed week 24 mTSS for missing week 24 values. A number of alternative methods of imputation, defining change from baseline mTSS for patients with fewer than two analysable mTSS were assessed as part of post hoc analyses including substituting by mean or median or maximum (see <xref ref-type="table" rid="ANNRHEUMDIS2013203697TB1">table 1</xref> for all different options). For all post hoc analyses, the mTSS had to be obtained at least 8&#x02005;weeks apart.</p><table-wrap id="ANNRHEUMDIS2013203697TB1" position="float"><label>Table&#x000a0;1</label><caption><p>Post hoc analyses of change from baseline at week 24 in mTSS</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" colspan="2" rowspan="2">Imputation in patients with &#x0003c;2 analysable mTSS*</th><th align="left" colspan="4" rowspan="1">mTSS change from BL at week 24</th></tr><tr><th align="left" rowspan="1" colspan="1">Placebo (n=136)</th><th align="left" rowspan="1" colspan="1">CZP 200&#x02005;mg Q2W (n=138)</th><th align="left" rowspan="1" colspan="1">CZP 400&#x02005;mg Q4W (n=135)</th><th align="left" rowspan="1" colspan="1">CZP 200&#x02005;mg Q2W+CZP 400&#x02005;mg Q4W (n=273)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Prespecified&#x02020;</td><td rowspan="1" colspan="1">Minimum observed score (0) if missing BL<break/>Maximum observed score (356.5) if missing week 24</td><td rowspan="1" colspan="1">28.9 (7.73)</td><td rowspan="1" colspan="1">11.5 (7.59)<break/>p=0.071&#x02021;</td><td rowspan="1" colspan="1">25.1 (7.92)<break/>p=0.688&#x02021;</td><td rowspan="1" colspan="1">18.3 (6.07)<break/>p=0.203</td></tr><tr><td colspan="6" rowspan="1"><hr/></td></tr><tr><td rowspan="1" colspan="1">Post hoc 1&#x000a7;</td><td rowspan="1" colspan="1">No imputation</td><td rowspan="1" colspan="1">0.29 (0.08)</td><td rowspan="1" colspan="1">0.01 (0.08)<break/>p=0.004&#x02021;</td><td rowspan="1" colspan="1">0.12 (0.08)<break/>p=0.083&#x02021;</td><td rowspan="1" colspan="1">0.06 (0.06)<break/>p=0.008</td></tr><tr><td colspan="6" rowspan="1"/></tr><tr><td rowspan="1" colspan="1">Post hoc 2&#x000b6;</td><td rowspan="1" colspan="1">Median mTSS change from BL of all patients observed</td><td rowspan="1" colspan="1">0.28 (0.07)</td><td rowspan="1" colspan="1">0.01 (0.07)<break/>p=0.004&#x02021;</td><td rowspan="1" colspan="1">0.11 (0.08)<break/>p=0.072&#x02021;</td><td rowspan="1" colspan="1">0.06 (0.06)<break/>p=0.007</td></tr><tr><td colspan="6" rowspan="1"/></tr><tr><td rowspan="1" colspan="1">Post hoc 3&#x000b6;</td><td rowspan="1" colspan="1">Mean mTSS change from BL of all patients observed</td><td rowspan="1" colspan="1">0.28 (0.07)</td><td rowspan="1" colspan="1">0.01 (0.07)<break/>p=0.004&#x02021;</td><td rowspan="1" colspan="1">0.11 (0.08)<break/>p=0.072&#x02021;</td><td rowspan="1" colspan="1">0.06 (0.06)<break/>p=0.007</td></tr><tr><td colspan="6" rowspan="1"/></tr><tr><td rowspan="1" colspan="1">Post hoc 4&#x000b6;</td><td rowspan="1" colspan="1">Maximum mTSS change from BL of all patients observed</td><td rowspan="1" colspan="1">0.66 (0.13)</td><td rowspan="1" colspan="1">0.18 (0.13)<break/>p=0.003&#x02021;</td><td rowspan="1" colspan="1">0.52 (0.13)<break/>p=0.380&#x02021;</td><td rowspan="1" colspan="1">0.35 (0.10)<break/>p=0.028</td></tr><tr><td colspan="6" rowspan="1"/></tr><tr><td rowspan="1" colspan="1">Post hoc 5&#x000b6;</td><td rowspan="1" colspan="1">Maximum mTSS change from BL by treatment group</td><td rowspan="1" colspan="1">0.39 (0.11)</td><td rowspan="1" colspan="1">0.14 (0.11)<break/>p=0.077&#x02021;</td><td rowspan="1" colspan="1">0.49 (0.12)<break/>p=0.483&#x02021;</td><td rowspan="1" colspan="1">0.31 (0.09)<break/>p=0.538</td></tr></tbody></table><table-wrap-foot><fn><p>Values are least squares mean (SE). For placebo patients who escaped early to CZP, the week 24 values were linearly extrapolated. p Values of CZP versus placebo are based on analysis of covariance.</p></fn><fn><p>*For patients with two radiographs but missing week 24 or baseline film, linear extrapolation was performed in all approaches.</p></fn><fn><p>&#x02020;21 patients had fewer than two analysable mTSS; the number of patients was not equally distributed between the treatment groups.</p></fn><fn><p>&#x02021;The study was not powered to detect statistical significance between individual CZP dosage groups and placebo, therefore, these p values should be considered nominal.</p></fn><fn><p>&#x000a7;26 patients had fewer than two analysable mTSS more than 8&#x02005;weeks apart (required for post hoc analysis).</p></fn><fn><p>&#x000b6;28 patients had fewer than two analysable mTSS more than 8&#x02005;weeks apart, including two placebo patients who escaped to CZP before their second mTSS.</p></fn><fn><p>BL, baseline; CZP, certolizumab pegol; mTSS, modified Total Sharp Score; Q2W, every 2&#x02005;weeks; Q4W, every 4&#x02005;weeks.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3a"><title>Patients</title><p>The demographic and baseline characteristics of the treatment groups were generally well balanced (see online <ext-link ext-link-type="uri" xlink:href="http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-203697/-/DC1">supplementary table</ext-link> S1).<xref ref-type="bibr" rid="R8">8</xref> In total, 368 (90%) patients completed the 24-week, double-blind phase of the study.<xref ref-type="bibr" rid="R8">8</xref></p><p>Overall, 21 patients had no or one available mTSS (eight placebo, four CZP 200&#x02005;mg Q2W, nine CZP 400&#x02005;mg Q4W) (see online <ext-link ext-link-type="uri" xlink:href="http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-203697/-/DC1">supplementary figure</ext-link> S1). An additional five patients had two mTSS less than 8&#x02005;weeks apart (range 1&#x02212;6&#x02005;weeks), and two placebo patients escaped to active treatment without a week 12 mTSS (see online <ext-link ext-link-type="uri" xlink:href="http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-203697/-/DC1">supplementary figure</ext-link> S1).</p></sec><sec id="s3b"><title>Treatment efficacy (prespecified analyses)</title><p>Most patients experienced no change in mTSS over 24&#x02005;weeks (<xref ref-type="fig" rid="ANNRHEUMDIS2013203697F1">figure 1</xref>A). Overall, 27 patients had an mTSS of 0 at baseline; none of these patients had experienced mTSS progression by week 24. One patient was scored with a &#x02212;1 improvement in mTSS at week 1; linear extrapolation resulted in an unrealistic improvement of &#x02212;24 points over 24&#x02005;weeks (<xref ref-type="fig" rid="ANNRHEUMDIS2013203697F1">figure 1</xref>A).</p><fig id="ANNRHEUMDIS2013203697F1" position="float"><label>Figure&#x000a0;1</label><caption><p>Cumulative probability plots of modified Total Sharp Score (mTSS) total change, with data from patients with fewer than two available radiographs (A) imputed using prespecified imputation method, (B) not imputed, (C) imputed using median mTSS change from baseline of observed patients, (D) imputed using mean mTSS change from baseline of observed patients, (E) imputed using maximum mTSS change from baseline of observed patients and (F) imputed using maximum mTSS change from baseline by treatment group. CZP, certolizumab pegol; Q2W, every 2&#x02005;weeks; Q4W, every 4&#x02005;weeks.</p></caption><graphic xlink:href="annrheumdis-2013-203697f01"/></fig><p>At baseline, the lowest observed mTSS was 0. At 24&#x02005;weeks, the largest was 356.5. Consequently, four patients without mTSS were assigned a progression of 356.5. In addition, 16 patients with only analysable baseline mTSS were assigned mTSS progressions ranging from 287.5 to 356.5 (<xref ref-type="fig" rid="ANNRHEUMDIS2013203697F1">figure 1</xref>A). The imputation methodology led to an estimated mean mTSS change from baseline of 11.5 (CZP 200&#x02005;mg Q2W) and 25.1 (CZP 400&#x02005;mg Q4W) vs 28.9 (placebo) (<xref ref-type="table" rid="ANNRHEUMDIS2013203697TB1">table 1</xref>). This result was considered an unrealistic overestimation given that the largest observed change in mTSS in any group was 9, and most patients experienced no change in mTSS over 24&#x02005;weeks and this amount of progression has never been observed in any other study.</p><p>Using the prespecified mTSS non-progressor rate definition (&#x02264;0 cut-off, NRI), we found that mTSS non-progression was more common in the CZP arms than the placebo arms (83.3% (CZP 200&#x02005;mg Q2W) and 76.3% (CZP 400&#x02005;mg Q4W) vs 34.6% (placebo), p&#x0003c;0.001).</p></sec><sec id="s3c"><title>Treatment efficacy (post hoc analyses)</title><p>Post hoc analysis using the median mTSS of the entire population to impute missing values in patients with fewer than two analysable mTSS suggested that patients treated with CZP 200&#x02005;mg Q2W and CZP 400&#x02005;mg Q4W had reduced radiographic progression compared with placebo patients (0.01 (p=0.004) and 0.11 (p=0.072) vs 0.28) (<xref ref-type="fig" rid="ANNRHEUMDIS2013203697F1">figure 1</xref>C). Additional, more conservative post hoc analyses using alternative imputation methods confirmed the inhibition of radiographic progression by CZP (<xref ref-type="table" rid="ANNRHEUMDIS2013203697TB1">table 1</xref>, <xref ref-type="fig" rid="ANNRHEUMDIS2013203697F1">figure 1</xref>).</p><p>Baseline CRP and mTSS have previously been demonstrated to influence radiographic progression. Placebo patients with CRP&#x0003e;15&#x02005;mg/L and those with mTSS &#x0003e;6 (median population baseline score) experienced greater mTSS progression than those with CRP levels &#x02264;15&#x02005;mg/L (0.51 vs 0.12) and mTSS &#x02264;6 (0.54 vs 0.06). In comparison, CZP-treated patients experienced low mTSS progression irrespective of baseline CRP (0.08 vs 0.03) or mTSS at baseline (0.08 vs 0.04, see online supplementary table S2).</p><p>The proportion of mTSS non-progressors (&#x02264;0.5 points cut-off, linear extrapolation) remained significantly higher in the CZP group (93.5% (CZP 200&#x02005;mg Q2W) and 90.4% (CZP 400&#x02005;mg Q4W) vs 80.1% (placebo), p&#x0003c;0.05) and was not sensitive to the imputation methodology used for patients with fewer than two analysable mTSS (<xref ref-type="table" rid="ANNRHEUMDIS2013203697TB2">table 2</xref>). Subgroup analysis of mTSS non-progression demonstrated a similar pattern to that observed for mTSS change from baseline (see online supplementary table S2).</p><table-wrap id="ANNRHEUMDIS2013203697TB2" position="float"><label>Table&#x000a0;2</label><caption><p>mTSS non-progression analysis</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="3" rowspan="1">mTSS non-progressor rate (%)</th></tr><tr><th align="left" rowspan="1" colspan="1">Non-progressor cut-off (mTSS)</th><th align="left" rowspan="1" colspan="1">Imputation of missing values</th><th align="left" rowspan="1" colspan="1">Placebo (n=136)</th><th align="left" rowspan="1" colspan="1">CZP 200&#x02005;mg Q2W (n=138)</th><th align="left" rowspan="1" colspan="1">CZP 400&#x02005;mg Q4W (n=135)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">0&#x02020;</td><td rowspan="1" colspan="1">&#x02265;2 mTSS: NRI&#x02021;&#x000a7;<break/>&#x0003c;2 mTSS: considered progressors&#x02021;</td><td rowspan="1" colspan="1">34.6</td><td rowspan="1" colspan="1">83.3*</td><td rowspan="1" colspan="1">76.3*</td></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td rowspan="1" colspan="1">0&#x02020;</td><td rowspan="1" colspan="1">&#x02265;2 mTSS: linear imputation<break/>&#x0003c;2 mTSS: no imputation</td><td rowspan="1" colspan="1">81.9</td><td rowspan="1" colspan="1">91.7*</td><td rowspan="1" colspan="1">87.8</td></tr><tr><td colspan="5" rowspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02264;0.5</td><td rowspan="1" colspan="1">&#x02265;2 mTSS: linear imputation<break/>&#x0003c;2 mTSS: no imputation</td><td rowspan="1" colspan="1">86.6</td><td rowspan="1" colspan="1">96.2*</td><td rowspan="1" colspan="1">96.7*</td></tr><tr><td colspan="5" rowspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02264;0.5</td><td rowspan="1" colspan="1">&#x02265;2 mTSS: linear imputation<break/>&#x0003c;2 mTSS: mean mTSS change from BL of all patients observed</td><td rowspan="1" colspan="1">87.5</td><td rowspan="1" colspan="1">96.4*</td><td rowspan="1" colspan="1">97.0*</td></tr><tr><td colspan="5" rowspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02264;0.5</td><td rowspan="1" colspan="1">&#x02265;2 mTSS: linear imputation<break/>&#x0003c;2 mTSS: median mTSS change from BL of all patients observed</td><td rowspan="1" colspan="1">87.5</td><td rowspan="1" colspan="1">96.4*</td><td rowspan="1" colspan="1">97.0*</td></tr><tr><td colspan="5" rowspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02264;0.5</td><td rowspan="1" colspan="1">&#x02265;2 mTSS: linear imputation<break/>&#x0003c;2 mTSS: maximum mTSS change from BL of all patients observed</td><td rowspan="1" colspan="1">79.4</td><td rowspan="1" colspan="1">92.8*</td><td rowspan="1" colspan="1">88.1</td></tr></tbody></table><table-wrap-foot><fn><p>For placebo patients who escaped early to CZP, the week 24 values were linearly extrapolated.</p></fn><fn><p>*p&#x0003c;0.05 versus placebo.</p></fn><fn><p>&#x02020;Prespecified non-progressor cut-off mTSS.</p></fn><fn><p>&#x02021;Prespecified imputation.</p></fn><fn><p>&#x000a7;Patients with missing values considered progressors.</p></fn><fn><p>BL, baseline; CZP, certolizumab pegol; mTSS, modified Total Sharp Score; NRI, non-responder imputation; Q2W, every 2&#x02005;weeks; Q4W, every 4&#x02005;weeks.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>Linear interpolation and extrapolation of imaging data is a well-established imputation method in both rheumatoid arthritis and PsA clinical trials.<xref ref-type="bibr" rid="R6">6</xref>
<xref ref-type="bibr" rid="R12">12</xref>
<xref ref-type="bibr" rid="R13">13</xref> However, it requires the availability of two or more mTSS.<xref ref-type="bibr" rid="R1">1</xref>
<xref ref-type="bibr" rid="R3">3</xref>
<xref ref-type="bibr" rid="R4">4</xref> Furthermore, it has limitations when available mTSS are recorded very close together, demonstrated by the prespecified mTSS analysis of the RAPID-PsA trial. Excluding mTSS recorded &#x0003c;8&#x02005;weeks apart resulted in a more realistic estimate of progression in this population.</p><p>Analyses that include patients regardless of radiograph availability require additional imputation assumptions. These additional imputation methodologies can have a substantial impact on the assessment of mTSS progression. In this study, the assessment of CZP efficacy was confounded by an inappropriate imputation approach. The prespecified methodology imputed a change variable (mTSS progression) in a patient by replacing status variables (mTSS) across patients. Since the variation in mTSS between patients was many orders of magnitude greater than the average progression, assignment of mTSS progression in patients with fewer than two available mTSS was unrealistic and resulted in an overestimation of mTSS progression in all study arms, preventing the detection of treatment efficacy.</p><p>Post hoc analyses demonstrated that imputation methodologies that use the mTSS progression of a population, as has been used in other recent PsA trials,<xref ref-type="bibr" rid="R5">5</xref>
<xref ref-type="bibr" rid="R6">6</xref>&#x000a0;resulted in a more realistic estimate of whole population progression. However, a limitation of the RAPID-PsA post hoc analysis is that only a subset of possible imputation rules has been explored.</p><p>The rate of mTSS non-progression demonstrated a statistically significant difference between the CZP treatment arms and the placebo arm regardless of imputation approach. However, the prespecified imputation methodology, which considered all patients who withdrew or escaped to active treatment as mTSS progressors, is likely to overestimate the progression seen in placebo patients.</p><p>In conclusion, RAPID-PsA trial results demonstrate how significantly imputation methodology can influence the interpretation of radiographic outcomes in clinical trials. The &#x02018;no imputation&#x02019; approach for patients with no or only one film, or two films less than 8&#x02005;weeks apart and linear extrapolation for patients with two films at least 8&#x02005;weeks apart seems to be the most appropriate primary analysis. The other imputation methods should be used as sensitivity analyses.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><caption><title>Web supplement</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="annrheumdis-2013-203697-s1.pdf" xlink:type="simple" id="d35e849" position="anchor"/></supplementary-material></sec></body><back><fn-group><fn><p><bold>Correction notice:</bold> This article has been corrected twice since it was published Online First. The length of the study has been amended from 158 weeks to 216 weeks, and the value for the pre-specified mTSS non-responder cut-off should read &#x02018;&#x02264;0&#x02019; in the &#x02018;Treatment efficacy (prespecified analyses)&#x02019; section of the paper.</p></fn><fn><p><bold>Acknowledgements:</bold> The authors acknowledge Marine Champsaur, UCB Pharma, Brussels, Belgium for publication coordination and Costello Medical Consulting, UK, for writing and editorial assistance.</p></fn><fn><p><bold>Funding:</bold> The RAPID-PsA study was funded by UCB Pharma. Writing and Editorial Assistance was funded by UCB Pharma.</p></fn><fn><p><bold>Competing interests:</bold> UCB Pharma sponsored the trial and was responsible for data collection and analysis. The authors and the sponsor designed the study, interpreted the data, prepared the manuscript, and decided to publish.</p></fn><fn><p><bold>Ethics approval:</bold> National and Regional Ethics Committee or Institutional Review Board (Global Study).</p></fn><fn><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Van Der Heijde</surname><given-names>D</given-names></name></person-group>
<article-title>Use of imaging as an outcome measure in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis in clinical trials</article-title>. In: <person-group person-group-type="editor"><name><surname>Hochberg</surname><given-names>MC</given-names></name><name><surname>Silman</surname><given-names>AJ</given-names></name><name><surname>Smolen</surname><given-names>JS</given-names></name><etal/></person-group> eds. <source>Rheumatology</source>. <edition>5th edn.</edition>
<publisher-name>Elsevier</publisher-name>, <year>2011</year>:<fpage>413</fpage>&#x02013;<lpage>24</lpage></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kavanaugh</surname><given-names>A</given-names></name><name><surname>McInnes</surname><given-names>I</given-names></name><name><surname>Mease</surname><given-names>PJ</given-names></name><etal/></person-group>
<article-title>Golimumab, a new human tumor necrosis factor &#x003b1; antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four&#x02013;week efficacy and safety results of a randomized, placebo-controlled study</article-title>. <source>Arthritis Rheum</source>
<year>2009</year>;<volume>60</volume>:<fpage>976</fpage>&#x02013;<lpage>86</lpage><pub-id pub-id-type="pmid">19333944</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mease</surname><given-names>PJ</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Ritchlin</surname><given-names>CT</given-names></name><etal/></person-group>
<article-title>Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial</article-title>. <source>Arthritis Rheum</source>
<year>2005</year>;<volume>52</volume>:<fpage>3279</fpage>&#x02013;<lpage>89</lpage><pub-id pub-id-type="pmid">16200601</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kavanaugh</surname><given-names>A</given-names></name><name><surname>Antoni</surname><given-names>CE</given-names></name><name><surname>Gladman</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year</article-title>. <source>Ann Rheum Dis</source>
<year>2006</year>;<volume>65</volume>:<fpage>1038</fpage>&#x02013;<lpage>43</lpage><pub-id pub-id-type="pmid">16439444</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kavanaugh</surname><given-names>A</given-names></name><name><surname>van der Heijde</surname><given-names>D</given-names></name><name><surname>McInnes</surname><given-names>IB</given-names></name><etal/></person-group>
<article-title>Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial</article-title>. <source>Arthritis Rheum</source>
<year>2012</year>;<volume>64</volume>:<fpage>2504</fpage>&#x02013;<lpage>17</lpage><pub-id pub-id-type="pmid">22378566</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Heijde</surname><given-names>D</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Fleischmann</surname><given-names>RM</given-names></name><etal/></person-group>
<article-title>Tofacitinib, an oral Janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: year 2 efficacy and safety results from a 24-month phase 3 study</article-title>. <source>Arthritis Rheum</source>
<year>2012</year>;<volume>64</volume>:<fpage>546</fpage></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antoni</surname><given-names>C</given-names></name><name><surname>Krueger</surname><given-names>GG</given-names></name><name><surname>de Vlam</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial</article-title>. <source>Ann Rheum Dis</source>
<year>2005</year>;<volume>64</volume>:<fpage>1150</fpage>&#x02013;<lpage>57</lpage><pub-id pub-id-type="pmid">15677701</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mease</surname><given-names>PJ</given-names></name><name><surname>Fleischmann</surname><given-names>R</given-names></name><name><surname>Deodhar</surname><given-names>AA</given-names></name><etal/></person-group>
<article-title>Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24 week results of a phase III double-blind randomised placebo-controlled study (RAPID-PsA)</article-title>. <source>Ann Rheum Dis</source>
<comment>2014;73:48&#x02013;55</comment></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>W</given-names></name><name><surname>Gladman</surname><given-names>D</given-names></name><name><surname>Helliwell</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Classification criteria for psoriatic arthritis: development of new criteria from a large international study</article-title>. <source>Arthritis Rheum</source>
<year>2006</year>;<volume>54</volume>:<fpage>2665</fpage>&#x02013;<lpage>73</lpage><pub-id pub-id-type="pmid">16871531</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Heijde</surname><given-names>D</given-names></name><name><surname>Sharp</surname><given-names>J</given-names></name><name><surname>Wassenberg</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Psoriatic arthritis imaging: a review of scoring methods</article-title>. <source>Ann Rheum Dis</source>
<year>2005</year>;<volume>64</volume>(<issue>Suppl 2</issue>):<fpage>ii61</fpage>&#x02013;<lpage>4</lpage><pub-id pub-id-type="pmid">15708940</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Heijde</surname><given-names>D</given-names></name><name><surname>Simon</surname><given-names>L</given-names></name><name><surname>Smolen</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion</article-title>. <source>Arthritis Rheum</source>
<year>2002</year>;<volume>47</volume>:<fpage>215</fpage>&#x02013;<lpage>18</lpage><pub-id pub-id-type="pmid">11954017</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smolen</surname><given-names>J</given-names></name><name><surname>Landew&#x000e9;</surname><given-names>RB</given-names></name><name><surname>Mease</surname><given-names>PJ</given-names></name><etal/></person-group>
<article-title>Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial</article-title>. <source>Ann Rheum Dis</source>
<year>2009</year>;<volume>68</volume>:<fpage>797</fpage><pub-id pub-id-type="pmid">19015207</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keystone</surname><given-names>E</given-names></name><name><surname>van der Heijde</surname><given-names>D</given-names></name><name><surname>Mason</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study</article-title>. <source>Arthritis Rheum</source>
<year>2008</year>;<volume>58</volume>:<fpage>3319</fpage>&#x02013;<lpage>29</lpage><pub-id pub-id-type="pmid">18975346</pub-id></mixed-citation></ref></ref-list></back></article>